TREATMENT OF ACUTE MEDICAL CONDITIONS

1 . A computer-implemented method for treating an acute medical condition involving stimulating neural activity of a splenic arterial nerve, wherein the splenic arterial nerve is associated with a neurovascular bundle, the method comprising:

controlling operation of at least one electrode in signaling contact with the splenic arterial nerve, wherein at least one controller is electrically coupled to the at least one electrode and configured to control operation of the at least one electrode to apply an electrical signal to the splenic arterial nerve, such that the neural activity of the splenic arterial nerve is reversibly stimulated, wherein the electrical signal has a waveform that comprises one or more pulse trains, and

applying a charge density per phase to the nerve, wherein the charge density applied to the nerve by the electrical signal is ≥70 μC per cm 2 per phase and ≤1300 μC per cm 2 per phase,

wherein the electrical signal produces an improvement in a physiological parameter indicative of treatment of the acute medical condition, wherein the improvement in the physiological parameter is any of a group consisting of: restoring a body temperature to between 36° C. and 38° C., restoring a heart rate to 60-100 bpm, restoring a systemic arterial pressure to between 90/60 mmHg and 150/90 mmHg, restoring a systemic venous pressure to about 5 mmHg in a right atrium and about 8 mmHg in a left atrium, restoring a pulmonary pressure to about 15 mmHg, restoring a central venous pressure to in a range of about 3 to 8 mmHg, restoring a breathing rate to 8-14 breaths per minute, an increase in oxygen saturation to ≥94%, an increase in an arterial partial pressure of oxygen to 12-15 kPa, restoring an arterial partial pressure of carbon dioxide to 4.4-6.1 kPa, a reduction of pain sensation, restoring urine output to ≥0.5 ml/kg/hr, increasing a level of consciousness, a reduction in a level of lactate, a change in a level of blood glucose, a change in a level of base deficit in blood and a change in a level of arterial pH, restoring lower levels of pulmonary vascular resistance while increasing systemic vascular resistance and increasing pulmonary capillary wedge pressure, reducing high levels of lipases, and reducing high levels of amylases.

2 . The method of claim 1 , wherein the acute medical condition is trauma.

3 . The method of claim 2 , wherein the trauma is blunt trauma, penetrating trauma, blast injury or burns.

4 . The method of claim 1 , wherein the acute medical condition is shock.

5 . The method of claim 4 , wherein the shock is anaphylactic shock, toxic shock syndrome, cardiogenic shock, hypovolemic shock, neurogenic shock, or endotoxic shock.

6 . The method of claim 1 , wherein the acute medical condition is an effect of a bacterial endotoxin.

7 . The method of claim 1 , wherein the acute medical condition is allograph/graph rejection.

8 . The method of claim 1 , wherein the acute medical condition is hemorrhaging.

9 . The method of claim 1 , wherein the acute medical condition is severe episodes of lupus.

10 . The method of claim 1 , further comprising the step of providing a neural interface, the neural interface comprising at least one electrode.

11 . The method of claim 10 , wherein the neural interface is placed on the splenic artery.

12 . The method of claim 10 , where in the neural interface is placed around the splenic artery.

13 . The method of claim 10 , wherein the neural interface comprises a catheter.

14 . The method of claim 10 , wherein the neural interface comprises a probe-type interface.

15 . The method of claim 10 , wherein the neural interface comprises a mesh electrode.

16 . The method of claim 10 , wherein the neural interface comprises a linear rod shaped lead.